Daxdilimab

Phase 2Monoclonal antibody

Amgen

Daxdilimab is one of 142 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

141

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Discoid Lupus ErythematosusActive, not recruiting

Alopecia AreataActive, not recruiting

Lupus NephritisActive, not recruiting

DermatomyositisActive, not recruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

Discoid Lupus ErythematosusPhase 2

Active, not recruiting

Alopecia AreataPhase 2

Active, not recruiting

Lupus NephritisPhase 2

Active, not recruiting

DermatomyositisPhase 2

Active, not recruiting

Competition

Competitive Landscape

328 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Eptanemab

UCB

Phase 3

12 2

Rituxan

Roche

Phase 3

9 3

Medrol

Pfizer

Phase 3

5 4

Olumiant

Eli Lilly

Phase 3

4 5

Ocrevus

Roche

Phase 3

2 6

Cytoxan

BBaxter Healthcare Corporation

Phase 3

11 7

Intrarosa

Alnylam Pharmaceuticals

Phase 3

1 8

Depo-Provera

Cellcept

Imuran

LLegacy Health System

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study

Terminated· Amgen logo

Amgen·Phase 2·NCT05430854·155 enrolled

Alopecia Areata1 trial

Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

Completed· Amgen logo

Amgen·Phase 2·NCT05368103·30 enrolled

Lupus Nephritis1 trial

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Terminated· Amgen logo

Amgen·Phase 2·NCT05540665·19 enrolled

Discoid Lupus Erythematosus1 trial

Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus

Terminated· Amgen logo

Amgen·Phase 2·NCT05591222·72 enrolled

Dermatomyositis1 trial

A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Completed· Amgen logo

Amgen·Phase 2·NCT05669014·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Daxdilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Daxdilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Daxdilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Amgen

Daxdilimab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

Alopecia Areata1 trial

Lupus Nephritis1 trial

Discoid Lupus Erythematosus1 trial

Dermatomyositis1 trial

References

Drug Info

Quick Facts

Related News